0.05Open0.05Pre Close0 Volume34 Open Interest2.50Strike Price0.00Turnover189.18%IV47.54%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0492Delta0.0498Gamma93.40Leverage Ratio-0.0052Theta-0.0001Rho-4.60Eff Leverage0.0011Vega
Monte Rosa Therapeutics Stock Discussion
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics presented preclinical data at EULAR 2024, showing that MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits rheumatoid arthritis progression in a murine model. The data indicated reduced serum pro-inflammatory cytokines and anti-collagen II autoantibodies. MRT-6160 de...
NEWS
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics has presented preclinical data on their molecular glue degrader, MRT-6160, at Digestive Disease Week 2024. MRT-6160 targets VAV1, a protein involved in autoimmune and inflammatory diseases like colitis. The study showed significant results, including reduced disease progressi...
No comment yet